Results 161 to 170 of about 40,241 (253)

P1107 Biosimilar but not quite the same?: Post-induction levels of infliximab differ between brands [PDF]

Prashant Patel, M Love, Peter J. Rimmer, Rachel Cooney, Karl Hazel   +4 more
openalex   +1 more source

Savings from biosimilars and Medicare formulary access. [PDF]

Health Aff Sch
Axelsen K, Courmier D, Bai G, Maini L.
europepmc   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]

Saudi Pharm J
Shan H, Guo Z, Ye X, Du Q, Liu J, Wang M.   +5 more
europepmc   +1 more source

Out of the Straitjacket. [PDF]

, 2018
Weinstein, Michael
core   +2 more sources

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. [PDF]

Sci Rep
Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, Jeong A, Sharma A, Kim JH, Sagong M, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +11 more
europepmc   +1 more source

Sicherheit und Wirksamkeit des Rituximab-Biosimilars Truxima® bei CD20-positiven Non-Hodgkin-Lymphomen und chronisch lymphatischer Leukämie im Rahmen der TRUDY-Registerstudie [PDF]

Sarah Schmidt
openalex   +1 more source

Expanding Horizons in Severe Asthma: Anti-IgE Biosimilars and the Redefinition of Patient Selection. [PDF]

Allergy Asthma Immunol Res
Yun JE, Song WJ.
europepmc   +1 more source

Biosimilars in der Schweiz : Medizin gegen die steigenden Gesundheitskosten? [PDF]

, 2020
Kobler, Irene, Lenzin, Golda, Liberatore, Florian, Pöhlmann, Johannes, Schmidt, Marion, Wieser, Simon   +5 more
core   +1 more source

Biosimilars: Approval and Acceptance? [PDF]

, 2011
Jessica K. DeMartino
openalex   +1 more source